Publications by authors named "David J Hallett"

Claim this Profile
P
Publisher Correction: Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.
Martin A Redhead, C David Owen, Lennart Brewitz, Amelia H Collette, Petra Lukacik, David J Hallett

Sci Rep· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.
Martin A Redhead, C David Owen, Lennart Brewitz, Amelia H Collette, Petra Lukacik, David J Hallett

Sci Rep· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remote stereocontrol in reactions between 4- and 5-alkoxyalk-2-enylstannanes and 1-alkoxycarbonylimines and analogues: stereoselective approaches to novel α-amino acids.
David J Hallett, Nongluk Tanikkul, Eric J Thomas

Org Biomol Chem· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-based discovery and optimization of BACE1 inhibitors.
James Madden, Jenny R Dod, Robert Godemann, Joachim Kraemer, Myron Smith, David J Hallett

Bioorg Med Chem Lett· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.
Adam J Davenport, Christopher C Stimson, Massimo Corsi, Darshan Vaidya, Edward Glenn, David J Hallett

Bioorg Med Chem Lett· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands.
Rosa L Fradley, Martin R Guscott, Sharlene Bull, David J Hallett, Simon C Goodacre

J Psychopharmacol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of GABAbeta2 subunit-containing receptors in mediating the anticonvulsant and sedative effects of loreclezole.
James O Groves, Martin R Guscott, David J Hallett, Thomas W Rosahl, Andrew Pike

Eur J Neurosci· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.
Richard T Lewis, Wesley P Blackaby, Timothy Blackburn, Andrew S R Jennings, Andrew Pike, David J Hallett

J Med Chem· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones as alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.
Simon C Goodacre, David J Hallett, Robert W Carling, José L Castro, David S Reynolds

Bioorg Med Chem Lett· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazo[1,2-b][1,2,4]triazines as alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.
Andrew S R Jennings, Richard T Lewis, Michael G N Russell, David J Hallett, Leslie J Street

Bioorg Med Chem Lett· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazo[1,2-a]pyrimidines as functionally selective GABA(A) ligands.
Wesley P Blackaby, John R Atack, Frances Bromidge, José L Castro, Simon C Goodacre, David J Hallett

Bioorg Med Chem Lett· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxiety.
Michael G N Russell, Robert W Carling, Leslie J Street, David J Hallett, Simon Goodacre

J Med Chem· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders.
Simon C Goodacre, Leslie J Street, David J Hallett, James M Crawforth, Sarah Kelly

J Med Chem· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis